Home

BioLexis Pte Ltd.

CIK 1716335 · Chief Executive Officer · last filed 2022-04-22

BioLexis Pte Ltd. is a Chief Executive Officer who has filed 10 SEC Form 4 insider transactions across 4 companies since 2017. The most recent filing, for OTLK, was dated Apr 22, 2022. Current disclosed insider exposure totals $765.9K across reported positions. The firm reports its address in Singapore, U0. 20 SEC filings were submitted jointly with Arun Kumar Pillai.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$765.9K

Companies

4

Total Filings

10

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
36 ROBINSON ROAD, #13-01 CITY HOUSE
SINGAPORE, U0 068877
Phone
962 6 582 7999
State of Incorporation
Singapore
Formerly Known As
BioLexis Pte Ltd. (2018–2022)
GMS Tenshi Holdings Pte. Ltd (2017–2018)
Related Filers
Arun Kumar Pillai — 20 joint filings, latest 2020-03-23
Ghiath M. Sukhtian — 13 joint filings, latest 2020-03-23
Faisal Ghiath Sukhtian — 7 joint filings, latest 2019-02-05
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
OTLK 10%+ Owner 1,149,126 $0.67 $765.9K $0 1 2022-04-22
Outlook Therapeutics, Inc. (OTLKW) Delisted Director 21,606,437 $0.03 $648.2K $0 7 2020-01-29
Outlook Therapeutics, Inc. (ONSIW) Delisted 10%+ Owner — — — $0 1 2018-10-02
Outlook Therapeutics, Inc. (ONSIZ) Delisted Chief Executive Officer — — — $0 1 2017-11-01

Recent Filings

10 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-04-22 OTLK Other (J) −27,982,529 $0 EDGAR
2020-01-29 Outlook Therapeutics, Inc. (OTLKW) Delisted Mixed +13,973,556 $3.24M EDGAR
2019-07-01 Outlook Therapeutics, Inc. (OTLKW) Delisted Other (J) — $0 EDGAR
2019-04-02 Outlook Therapeutics, Inc. (OTLKW) Delisted Other (J) — $0 EDGAR
2019-01-03 Outlook Therapeutics, Inc. (OTLKW) Delisted Grant (A) +12,865,872 $12.00M EDGAR
2018-12-31 Outlook Therapeutics, Inc. (OTLKW) Delisted Other (J) — $0 EDGAR
2018-12-31 Outlook Therapeutics, Inc. (OTLKW) Delisted Other (J) — $0 EDGAR
2018-12-06 Outlook Therapeutics, Inc. (OTLKW) Delisted Grant (A) +12,865,872 $12.00M EDGAR
2018-10-02 Outlook Therapeutics, Inc. (ONSIW) Delisted Other (J) — $0 EDGAR
2017-11-01 Outlook Therapeutics, Inc. (ONSIZ) Delisted Buy (P) — $0 EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.